 PARIS and Cambridge, Mass., June 19, 2021 GLOBE NEWSWIRE -- Biophytis SA Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS, Biophytis or the Company, a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces a new line of financing through Bonds Redeemable in Cash and New and Existing Shares ORNANE with Atlas, a specialized investment fund based in New York United States, for 32 million the 2021 Atlas Contract. This line of financing will be used for further clinical development of Sarconeos BIO101 in sarcopenia following our SARA phase 2 results and for the next development steps of the product in COVID-19 following our COVA phase 2-3 results, as well as the financing of the Companys activities going forward. 